Premium
Effect of Antiarrhythmic Drugs on Defibrillation Threshold: Case Report of an Adverse Effect of Mexiletine and Review of the Literature
Author(s) -
MARINCHAK ROGER A.,
ERIEHLING TED D.,
KLINE RUTH ANN,
STOHLER JANE,
KOWEY PETER R.
Publication year - 1988
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/j.1540-8159.1988.tb03925.x
Subject(s) - medicine , mexiletine , amiodarone , defibrillation threshold , defibrillation , implantable cardioverter defibrillator , adverse effect , cardiology , drug , anesthesia , intensive care medicine , pharmacology , atrial fibrillation
Antiarrhythmic agents can influence defibrillation threshold (DFT). Basic research suggests that some class I drugs may have deleterious ejects by raising defibrillation energy requirements. Evaluation of this problem in man has been limited to reports of patients who were more difficult to cardiovert or defibrillate after treatment with amiodarone and class IC agents. In the present report, mexiletine appeared to be the probable cause of an important elevation of DFT in a patient undergoing replacement of a malfunctioning automatic implantable cardioverter/defibrillator [AICD]. This report and the accompanying literature review suggest that more information at both the basic and clinical levels is required. Retesting of device efficacy in terminating induced arrhythmia in the laboratory appears prudent in patients who require antiarrhythmic drug therapy subsequent to AICD implantation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom